4 days ago · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd [3] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.

4 days ago · Novo Nordisk A/S is an international pharmaceutical research, development, and manufacturing corporation established in 1989 through the merger of competing Danish companies Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium.

Mar 8, 2024 · First, Novo Nordisk, the company behind Ozempic and Wegovy, outgrew its native Denmark. Now, it’s bigger than Tesla. Shares in the pharmaceutical giant rose jumped more than 8% Thursday,...

We are a globally founded healthcare company with headquarters outside of Copenhagen, Denmark. Our US headquarters is based in Plainsboro, New Jersey. For more than 100 years, we have been driving change to defeat diabetes.

3 days ago · Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

6 days ago · This month on pharmaphorum, we explore the history of Danish pharmaceutical company, Novo Nordisk, which has been changing and advancing the diabetes treatment environment for 90 years....

Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.

Feb 12, 2024 · Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest about $35 billion by 2030, CEO Kasim Kutay told Reuters in an interview on Monday.